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Summary Cytotoxic drug resistance developing after chemotherapy is thought to be the main cause of
treatment failure in several human tumours, including small cell lung cancer (SCLC). Cell lines showing drug
resistapce following prolonged exposure to a single agent frequently acquire resistance to several functionally
unrelated drugs, the phenomenon of multi-drug resistance (MDR). Classical MDR is thought to arise from
changes effecting a reduction in intracellular availability of cytotoxic drugs. We describe a flow cytometry
(FCM) technique to monitor the MDR phenotype in drug resistant variants of SCLC and non-SCLC cell
lines. The technique is based on a multiparametric analysis of the nuclear binding of a model chemothera-
peutic agent, the fluorescent dye Hoechst 33342 (Ho342), which is capable of supra-vital staining of DNA in
intact, viable cells. A laboratory derived drug resistant SCLC cell line, H69/LX4, showed a significant (30%)
reduction in nuclear binding compared to the parental line H69/P. Exposure to verapamil (VPL) rapidly
increased (within 2min) nuclear binding of Ho342, and the new equilibrium of nuclear staining, attained
within 20min, remained lower than the level achieved in the parental cell line, suggesting some ability of H69/
LX4 to limit the effect of the drug efflux blocker. A drug resistant large cell carcinoma line showed only a
small reduction (10%) in nuclear binding when compared to the parent line, and this difference was not
altered by VPL. A drug resistant adenocarcinoma line showed less than 10% difference in nuclear binding
compared with the parental line and neither line was significantly affected by VPL treatment. Our findings
suggest that different mechanisms of resistance may occur in lung tumours of different tissue types. This
technique may be extended to the rapid and direct examination of biopsy specimens of human solid tumours
for evidence of multi-drug resistance.
Emergence of resistance to initially effective cytotoxic drugs
is a major cause of treatment failure in small cell lung
cancer, a disease characterised by high initial response rates
to chemotherapy but ultimately low incidence of long term
control. Frequently post-chemotherapy relapse is refractory
even to cytotoxic drugs to which the tumour has not
previously been exposed. In vitro models of drug resistance
have provided much information on the cellular pathways
which may be involved. Postulated mechanisms include:
reduced drug accumulation (Skovsgaard & Nissen, 1982;
Inaba et al., 1979), altered intracellular distribution of drug
(Supino et al., 1986), reduced DNA cleavage (Glisson et al.,
1986; Capranico et al., 1986; Supino et al., 1988) or altered
drug activity at other target sites (Potmesil et al., 1988). The
development of 'classical' multi-drug resistance (classical
MDR) is a frequent outcome after selection of resistance in
vitro, such a phenotype is thought to reflect the increased
efflux of cytotoxic drugs by an energy-dependent transport
mechanism involving membrane located P-glycoprotein (Ling
et al., 1974), a finding which has been confirmed in several
(Riordan & Ling, 1985), but not all (Slovak et al., 1988;
Mirski et al;, 1987), cell lines showing MDR.
The analysis of patterns of drug uptake is clearly funda-
mental to the study of chemo-responsiveness of tumour
populations, yet whole population extraction methods can-
not identify important differences in intracellular location of
the drug and are inappropriate where there is possible
cellular heterogeneity. This paper considers the use of multi-
parameter flow cytometry (FCM) to evaluate the MDR
phenotype in tumour cell populations, using a technique to
detect anomalies in nuclear accumulation of a model chemo-
therapeutic agent, Hoechst dye 33342 (Ho342). Ho342 is a
vital, DNA-specific, bis-benzimidazole dye, which shows
considerable fluorescence enhancement upon binding non-
covalently to the minor groove of the double helix, permit-
ting the flow cytometric determination of dye uptake and
subsequent interaction with a defined intracellular target.
The uptake of this agent has been shown to parallel that of
a number of cytotoxic drugs involved in MDR and to
correlate with cellular sensitivity to these drugs (Lalande et
al., 1981); it is also modified by those agents that are known
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to partially overcome the MDR phenotype (calmodulin
inhibitors and Ca2+ channel blockers; Krishan, 1987).
The Ho342-DNA fluorescence emission spectrum is known
to show a shift to longer wavelengths as the dye: DNA-
phosphate ratio increases (Smith et al., 1985), reflecting a
reduction in binding energy that occurs at higher concen-
trations of DNA-bound dye due to co-operativity between
ligand molecules. We have used the shift in fluorescence
.-emission spectrum which occurs at early time points after
H°342 treatment in the analysis of (i) changes in the
intracellular availability of this model cytotoxic agent in
human SCLC and non-SCLC lung cancer cell lines, and (ii) the
responsiveness of drug resistant cells to verapamil (VPL).
Materials and methods
Cell lines and culture conditions
Stock cultures of human cell lines were maintained in RPMI
medium supplemented with 10% fetal calf serum, penicillin
and streptomycin (all Gibco Europe Ltd), at 37°C in an 8%
Co2/92% air mixture. The origins and characteristics of the
cell lines are shown in Table I. NCI-H69/P (H69/P) and
H69/LX4 (LX4) grew as free-floating aggregates; COR-L23,
MOR and their drug resistant variants grew as adherent
monolayers. The procedure for the derivation of drug resis-
tant cell lines in this laboratory, by step-wise exposure to
increasing adriamycin (ADM) concentrations, has been
reported previously (Twentyman et al., 1986b). Resistant cell
lines were maintained under selective conditions with ADM
(Farmitalia Carlo Erba) at the concentrations shown. Cul-
tures were grown in non-selective medium for 24-72h before
an experiment. (Similar results were obtained for cells main-
tained under non-selective conditions for up to 7 days -
results not shown.)
Preparation and treatment of cultures
Cells were disaggregated using a 15min treatment with 0.4%
trypsin and 0.02% versene (Gibco Biocult) at 37°C. No
differences were seen in subsequent Ho342, uptake of H69/P
cells as a result of this preparatory method compared to
gentle disaggregation of loose aggregates by pipetting (results
not shown). Cells were washed and resuspended at 2 x 105
cells ml-' in complete culture medium supplemented with
10mM Hepes (N-2-hydroxyethylpiperazine-N-2-ethane sul-
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Figure 1 Time dependent increase in Ho342-DNA fluorescence of SCLC cells (H69/P 0; LX4 A) exposed to 1OpM dye.
Fluorescence values expressed as a percentage of the value obtained for H69/P cells at 40min as detailed in the text. Data points
are arithmetic means of six experiments; error bars show + 1 s.e.m.
phonic acid), and held under standard culture conditions for
a minimum of 30min before further manipulation.
Flow cytometric analyses
Cell cycle analysis A rapid one-step DNA-staining tech-
nique using ethidium bromide (50 gml-P Triton X-100
0.125%, ribonuclease 0.5pgml-1; 10min at room tempera-
ture) was used to measure DNA content by reference to
human peripheral blood leucocytes stained concurrently
(mean DNA content of 8.3pgcell- 1; Smith, 1985). Cell cycle
distribution was analysed by the computer algorithm de-
scribed previously (Watson et al., 1987).
Nuclear Ho342 accumulation The exact concentrations of
filter sterilised stock solutions of Ho342 (CP Laboratories,
Bishop's Stortford, UK) were determined spectrophoto-
metrically (molar extinction coefficient 4.1 x 104M-1 cm-1 at
340nm, pH7.0). All treatments were at 10/IM dye concen-
tration and at 37°C. Cells were exposed to 3.3 ggml-1
(6.6pM) VPL (Abbott Laboratories, Queensborough, Kent)
either for 30min before addition of Ho342, or at 25min after
H°342 treatment.
Cell suspensions were analyzed directly after fluorochrome
treatment using a flow cytometer, details of which have been
published previously (Watson, 1981), incorporating a high
light collection efficiency flow chamber (Watson, 1985).con-
sidered necessary for these experiments. Briefly, fluorescence
excitation was by a krypton laser tuned to 337nm (200mW
light power). Five parameters were recorded: 900 light scatter
(<370nm) acting as the master trigger, forward light scatter
and three fluorescence channels monitoring selected regions
of the Ho342-DNA emission spectrum (400nm, 500nm and
600nm, all 5nm). Sub-cellular debris and cell clumps were
excluded by electronic gating on the basis of light-scatter
signals and pulse-shape analysis (Watson et al., 1985).
Analysis was performed on two-dimensional displays of
fluorescence data (400nm versus 600nm) for each sample by
gating on regions of interest and obtaining median fluor-
escence values. To allow comparison of a series of Ho342
uptake experiments a standard sample of H69/P cells (after
40min fluorochrome treatment) was prepared for each
analysis, and median fluorescence results are quoted normal-
ised to this control value.
Results
The DNA content and cell cycle distribution of asynchro-
nously growing parent and resistant lines of both SCLC and
adenocarcinoma types were similar (Table I). The large cell
carcinoma line COR-L23 showed a greater G2/M proportion
and COR-L23R a greater G1 DNA content than H69/P, so
that the mean cellular DNA content of these lines was,
respectively, 1.5 and 1.8 times that of H69/P. As the level of
H°342 fluorescence is dependent on cellular DNA content -
as well as the intranuclear fluorochrome content - the
fluorescence values shown are corrected for the mean cellular
DNA content of the whole cell population with respect to
H69/P.
The increase in nuclear fluorescence of H69/P and LX4
cells as a function of exposure period to Ho342 is shown in
Figure 1. The drug resistant cell line showed a slower
Table I Tumour cell line characteristics
Mean DNA contentb
Cell line ADM Cell cycle distributionb (pg DNA cell-')
designation Origin resistancea %G1 %S %G2/M G1 Khole population
NCI/H69-P SCLCC _ 56 31 13 12.0 12.8
NCI/H69-LX4 Resistant SCLCC + 45 40 15 11.1 12.3
(85)
MOR AdenoCAd - 57 32 11 11.1 12.9
MOR-R Resistant AdenoCAd + 44 33 23 10.8 11.4
(12)
COR-L23 Large cell CAd - 22 34 44 11.1 19.8
COR-L23-R Resistant large cell CAd + 39 41 20 16.7 23.4
(11)
aFigures in brackets indicate resistance factor to Adriamycin (Twentyman et al., 1986b) determined as the ratio of
Adriamycin doses, for resistant compared to parent cell line, required to suppress cell numbers to 20% of control values
with continuous drug exposure. bDetermined by FCM, with reference to human leucocyte standard. cSCLC: small cell lung
cancer, cultured as free-floating aggregates. dCA: carcinoma, cultured as attached monolayers.
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Figure 2 Spectral shift of Ho342-DNA fluorescence with time
after dye exposure for SCLC cells. Results represent means of
ratios derived from six experiments (standardised to the H69/P
control; see legend to Figure 1). Symbols as in Figure 1.
development of fluorescence at all wavelengths (only 400nm
and 600nm are shown) which was most pronounced at
longer wavelengths (50% reduction at 600nm compared with
10% at 400nm). By considering the ratio of two fluorescence
values the influence of cellular DNA content on total
fluorescence is removed and different cell lines can be
directly compared on the basis of the rate at which ligand is
binding to DNA (i.e. the spectral shift). This change in
fluorescence spectrum, due to altered cellular content of the
dye, is demonstrated by considering the ratio of the 600nm
value to that at 400nm (Figure 2). After Ho342 treatment of
H69/P, a spectral shift occurred during the initial 20min time
interval, due to increasing dye-DNA binding, whereas the
drug resistant line LX4 showed no alteration of the fluor-
escence ratio during this period, reflecting a significant
limitation on the intracellular availability of the ligand for
interaction with DNA.
It was noted that a small proportion of cells in all
preparations showed instantaneous (<1 min) development of
fluorescence at both wavelengths simultaneously. These cells
are considered to be non-viable because they are unable to
provide any barrier to Ho342-DNA binding and simulta-
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neously show efficient staining with propidium iodide (data
not shown). The effect of even small numbers of these non-
viable cells was both to increase the whole population
fluorescence and to increase the apparent ratio of the
600nm/400nm fluorescence emission, particularly at early
time intervals after fluorochrome treatment. This signifi-
cantly alters the fluorescence ratio of the drug resistant line
LX4 because of the relatively low levels of absolute fluores-
cence, and would result in an overestimate of drug uptake
(e.g. the 2min time points in Figure 1). In all subsequent
analyses presented here cells showing instantaneous spectral
shift patterns after Ho342 treatment have been excluded by
dual parameter analysis as indicated in the Materials and
methods.
A 30min pretreatment of LX4 cells with VPL resulted in
increased Ho342-DNA fluorescence at all wavelengths on
subsequent fluorochrome treatment (see Figure 3), from 30
to 50% that of the H69/P control, indicating increased
intracellular availability of the fluorochrome; no significant
change was observed with H69/P given this treatment. The
time course of the effect of VPL on LX4 was clearly
demonstrated by adding VPL after 25min prior exposure to
fluorochrome, at which time both sensitive and ADM-
resistant lines had reached an equilibrium for Ho342-DNA
fluorescence (Figure4). Under these conditions the VPL-
induced increase in fluorescence of LX4 occurred at a rate as
rapid as the initial phase of H°342 uptake by H69/P. The
observed increase in the fluorescence ratio of LX4 reached a
new equilibrium value below that of the parent cell line
within 20 minutes of Ho342 addition, after which there was
no further change despite continued exposure to both VPL
and dye (Figure 5); clearly the treatment did not fully reverse
the phenotype of reduced intracellular availability of Ho342.
Further experiments demonstrated the fluorescence shift to
be VPL concentration dependent, but at higher concen-
trations abnormalities in the forward scatter characteristic,
and reduction in cell number that also occurred, suggested
that VPL was having toxic effects (results not shown).
We have attempted to demonstrate a similar mechanism of
reduced Ho342-DNA binding in drug resistant non-SCLC
lines COR-L23-R and MOR-R compared to the parent lines,
from which they had been derived by intermittent ADM
exposure in an identical manner to LX4. Both were found to
show much smaller differences in Ho3,2 DNA fluorescence
between the parent and corresponding drug resistant lines.
COR/L23 cells (large cell carcinoma; Figure 6a) showed a
plateau fluorescence value which was only slightly greater
than COR/L23-R (7% at 400nm and 2% at 600nm); MOR
Ho342 incubation period (min)
Figure 3 Effect of verapamil pre-treatment on Ho342-DNA fluorescence of SCLC cells (0, * H69/P; A,A LX4); median
fluorescence values (standardised to the H69/P control). Open symbols represent 1O HM H342 alone, closed symbols indicate
6.6pM verapamil for 30min before fluorochrome addition.HOECHST 33342 UPTAKE IN MULTI-DRUG RESISTANCE 285
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Figure 4 Effect of verapamil (6.6pM) on the development of Ho342-DNA fluorescence of SCLC lines: (a) H69/P, (b) LX4.
Emission at 400nm+5 (0,0), 500'nm+5 (A,A) and 600nm+5 (El,U) nm; with 10M Ho342 alone. Open symbols represent
1OpmM Ho342 alone, closed symbols indicate values after verapamil addition at 25min fluorochrome exposure.
cells (adeno-carcinoma; Figure 6b) showed approximately
10% greater fluorescence (11% at 400nm, 9% at 600nm)
than the drug resistant variant MOR-R.
VPL pretreatment of the drug resistant large cell carci-
noma line COR-L23-R resulted in a small increase in Ho342-
DNA fluorescence at all time intervals after fluorochrome
treatment (Figure 6a), but this was also detectable in the
parent line COR-L23, suggesting that the VPL modification
of intracellular availability of the dye was not a function of
the resistance phenotype in these cells. In contrast neither
adeno-carcinoma line, MOR and MOR-R, showed a signifi-
cant change in Ho342 fluorescence patterns following VPL
pretreatment (Figure 6b), suggesting that intracellular cyto-
toxic drug avilability is not a VPL sensitive process in either
of these cell lines.
Discussion
We have described the use of spectral shift analysis of
Ho342-DNA fluorescence for monitoring the classical MDR
phenotype in lung cancer cells. LX4, a SCLC cell line in
which exposure to ADM produced MDR, showed a reduced
uptake of Ho342 when compared to the parent line, H69/P.
In contrast only small differences were observed in Ho342-
DNA fluorescence in two non-SCLC lines, suggesting that
the mode of drug resistance in these non-SCLC cells was not
solely related to reduced intra-nuclear availability of cyto-
toxic drug.
The significant enhancement of Ho342 fluorescence on
binding to DNA allows assessment of the cellular content of
the agent at the putative site of action; potentially important
differences in sub-cellular localisation of cytotoxic agents are
not identified by other techniques of drug uptake analysis
currently employed. Our technique does not identify specific
mechanisms effecting the reduced nuclear concentration of
fluorochrome in a given cell line, for example reduced DNA-
fluorochrome binding by chromatin modification, or an
active efflux mechanism at either cell, or nuclear, membrane
sites. While assessment of whole cell uptake of ADM
(Twentyman et al., 1986b) gave similar results in the SCLC
cell lines as our method, showing a 50% reduction of ADM
content in LX4 compared to H69/P, the results for non-
SCLC cell lines were significantly diffeent, MOR-R showing
a 90% reduction and COR/L23-R a 60% reduction in whole
cell content of ADM compared to the parent cell line.
Further investigation is required to ensure that this differ-
ence is not because of methodological variations.
The mechanism limiting fluorochrome access to DNA in
LX4 was rapidly, but only partially, reversed by VPL, with a
new equilibrium of dye-DNA fluorescence being reached
after 20min, suggesting that the use of 30min pre-treatment
with VPL was sufficient to produce maximal effect of the
resistance modifier, at the concentration used, on the MDR
mechanism in these cells. The presence of two components of
MDR, only one of which is VPL sensitive, has been
postulated in other mammalian MDR cell lines (Warr et al.,
1988), although the kinetics of VPL activity on nuclear
accessibility has not been demonstrated previously. A smaller
and equal effect of VPL on the Ho342-DNA fluorescence of
the drug resistant and parent large cell carcinoma lines
suggests that the VPL-induced changes in Ho342-DNA
fluorescence may be mediated by a mechanism unrelated to
the resistance phenotype. Modification of ADM cytotoxicity
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Figure 5 Spectral shift analysis of the influence of verapamil
(6.6uM) on the development of Ho342-DNA fluorescence of
SCLC lines (H69/P 0,0; LX4 A,A). Open symbols indicate
values before and solid symbols values after verapamil addition.
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Figure 6 Time dependent increase in Ho342-DNA fluorescence of (a) large cell carcinoma cell lines, L23 (El, M) and L23-R
(O, *), (b) adenocarcinoma cell lines, MOR (E], M) and MOR-R (O>, *), exposed to 10M dye. Open symbols represent 1,0UM
H°342 alone, closed symbols indicate 6.6pM verapamil treatment for 30min before fluorochrome addition.
by VPL (at 6.6juM concentration) in these cell lines has been
reported previously (Twentyman et al., 1986a); the resistance
factor, as defined in Table I, was reduced 8-fold for LX4,
consistent with the VPL effect on nuclear fluorescence shown
by our technique. However, a 4-fold reduction in resistance
factor to ADM of MOR-R, and 3-fold reduction of resis-
tance factor of COR/L23-R were also described, which may
indicate a further chemosensitivity-modifying activity of VPL
other than by altered intra-nuclear drug accumulation, which
we were unable to demonstrate in these non-SCLC cell lines.
LX4 is known to show increased expression of mdr-I gene
encoding P170 membrane glycoprotein, demonstrated by
Western blot analysis using MoAb C219 and Northern blot
analysis using cDNA probe pHDR105 (Reeve et al., 1989),
and differs in this respect from both an ADM resistant
variant of NCI-H69 developed elsewhere (Mirski et al.,
1987), and from COR/L23-R, neither of which MDR lines
show enhanced P-glycoprotein levels (Reeve et al., 1988).
Results of further studies, currently being undertaken, of
mdr-J gene expression in MOR-R will be important in
defining the relationship between membrane protein changes
and Ho342-DNA fluorescence.
Monitoring of intact, viable cells by this FCM technique
can be readily performed because of the enhanced fluor-
escence of Ho342 when complexed with DNA, compared to
the low intrinsic fluorescence of cytotoxic drugs, such as
ADM, which requires highly cytotoxic concentrations of
drug to be used for FCM visualisation of uptake kinetics. In
addition we have used the instantaneous fluorochrome stain-
ing pattern (absence of spectral shift identified by multiple
wavelength FCM) to exclude non-viable cells from uptake
analysis. This novel approach abrogates an otherwise signifi-
cant over-estimation of dye uptake in mixed cell populations.
Importantly, following Ho342 identification of the MDR
phenotype, cells remain accessible to monoclonal antibody
analysis of surface or subcellular components, with
fluorescence-activated cell sorting providing a means of
separating drug resistant sub-populations for subsequent cell
culture or biochemical analysis.
Cellular features which may alter absolute values of
Ho342-DNA fluorescence are the total DNA content and the
frequency of preferential binding sites for the ligand; com-
parison of different cell lines by expressing fluorescence
results as the ratio of two fluorescence values removes these
potential influences. This approach could also be used in
complex cell samples, where light-scattering characteristics
alone are not sufficient to distinguish cell types. Differences
in the fluorescence emission spectrum, rate of increase of
fluorescence (Lalande et al., 1981) and total fluorescence
(Loken, 1980) can also be used to identify cell subsets.
Although there was no evidence within these cell lines of
sub-populations of cells with respect to drug uptake, the
rapidity of FCM should allow detection of even very low
frequency events, such as spontaneously occurring mutant
cells showing reduced drug uptake (Ross et al., 1988). It has
been postulated that within a heterogeneous population of
human tumour cells even small differences in cytotoxic drug
uptake, such as can be demonstrated by this technique, may
produce significant differences in clinical responsiveness to
cytotoxic drugs in vivo.
The cell of origin of SCLC is thought to differ from that
of non-SCLC, and the diseases are also distinguished by
clinical features including chemotherapeutic responsiveness.
Expression of the mdr gene is known to differ in normal
tissues from different sites (Fojo et al., 1987), perhaps
reflecting variation in tissue requirements for excretion of
toxic substances (Arly Nelson, 1988); a differential effect of a
cytotoxic agent producing the MDR phenotype, but with
changes in mdr-l expression and Ho342 accumulation
according to cell type, is not then unexpected, but the
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association observed in these lung cancer cell lines requires
further investigation. The generation of two MDR variants
from the same cell line (NCI-H69), showing similar degrees
of chemo-resistance but one showing mdr-I gene amplifica-
tion and expression (J.G. Reeve et al., manuscript in prep-
aration) and one not (Mirski, 1987), indicates the potential
for development of multiple mechanisms of drug resistance
within a single cell type. The significance of the MDR
mechanism, identified in vitro following prolonged exposure
to a single cytotoxic agent, to clinical patterns of drug
resistance developing in vivo after treatment with a number
of chemotherapy agents, given simultaneously and intermit-
tently, is uncertain; further study is required with samples
obtained directly from human solid tumours, for which the
technique described here appears to be particularly suitable.
We are grateful to Professor N.M. Bleehen for his helpful advice
and encouragement.
References
ARLY NELSON, J. (1988). A physiological function for multidrug-
resistant membrane glycoproteins: a hypothesis regarding the renal
organic cation-secretory system. Cancer Chemother. Pharmacol.,
22, 92.
CAPRANICO, G., DASDIA, T. & ZUNINO, F. (1986). Comparison of
doxorubicin-induced DNA damage in doxorubicin-sensitive and
-resistant P388. murine leukaemia cells. Int. J. Cancer, 37,
227.
FOJO, A.T., UEDA, K., SLAMON, D.J., POPLACK, D.G., GOTTESMAN,
M.M. & PASTAN, I. (1987). Expression of a multidrug-resistance
gene in human tumours and tissues. Proc. Natl Acad. Sci. USA,
84, 265.
GLISSON, B.S., GUPTA, R., SMALLWOOD-KENTRO, J. & ROSS, W.E.
(1986). Characterisation of acquired resistance in a Chinese
hamster ovary cell line: loss of drug-stimulated DNA cleavage
activity. Cancer Res., 46, 1934.
INABA, M., KOBAYASHI, H., SAKURAI, Y. & JOHNSON, R.I.C.
(1979). Active efflux of daunorubicin and adriamycin in sensitive
and resistant sublines of P388 leukaemia. Cancer Res., 39, 2200.
KRISHAN, A. (1987). Effect of drug efflux blockers on vital staining
of cellular DNA with Hoechst 33342. Cytometry, 8, 642.
LALANDE, M.E., LING, V. & MILLER, R.G. (1981). Hoechst 33342
dye uptake as a probe of membrane permeability changes in
mammalian cells. Proc. Natl Acad. Sci. USA, 78, 363.
LING, V., GERLACH, J. & KARTNER, N. (1984). Multidrug resis-
tance. Breast Cancer Res. Treat., 4, 89.
MIRSKI, S.E.L., GERLACH, J.H. & COLE, S.P.C. (1987). Multidrug
resistance in a human small cell lung cancer cell line selected in
Adriamycin. Cancer Res., 47, 2594.
LOKEN, M.R. (1980). Separation of viable T & B lymphocytes using
a cytochemical stain Hoechst 33342. J. Histochem. Cytochem.,
28, 36.
POTMESIL, M., HSIANG, Y.-H., LIU, L.F. & 9 others (1988). Resis-
tance of human leukaemic and normal lymphocytes to drug-
induced DNA cleavage and low levels of DNA topoisomerase II.
Cancer Res., 48, 3537.
REEVE, J.G., RABBITTS, P.H. & TWENTYMAN, P.R. (1988). Cellular
concomitants of multidrug resistance in a human large cell lung
carcinoma cell line. Lung Cancer, 4, A1l, 2.04.
REEVE, J.G., RABBITTS, P.H. & TWENTYMAN, P.R. (1989).
Amplification and expression of mdr-J gene in a multidrug-
resistant variant of a small cell lung cancer cell line NCI-H69.
Br. J. Cancer (in the press).
RIORDAN, J.R. & LING, V. (1985). Genetic and biochemical charac-
terization of multidrug resistance. Pharmacol. Ther., 28, 51.
ROSS, D.D., ORDONEZ, J.V., JONECKIS, C.C., TESTA, J.R. &
THOMPSON, B.W. (1988). Isolation of highly multi-drug resistant
P388 cells from drug-sensitive P388/S cells by flow cytometric
cell sorting. Cytometry, 9, 359.
SKOVSGAARD, T. & NISSEN, N.I. (1982). Membrane transport of
anthracyclines. Pharmacol. Ther., 18, 293.
SLOVAK, M.L., HOELTGE, G.A., DALTON, W.S. & TRENT, J.M.
(1988). Pharmacological and biological evidence for differing
mechanisms of doxorubicin resistance in two human tumor cell
lines. Cancer Res., 48, 2793.
SMITH, P.J., NAKEFF, A. & WATSON, J.V. (1985). Flow-cytometric
detection of changes in the fluorescence emission spectrum of a
vital DNA specific dye in human tumour cells. Exp. Cell Res.,
159, 37.
SUPINO, R., MARIANI, M., CAPRANICO, G., COLOMBO, A. &
PARMIANI, G. (1988). Doxorubicin cellular pharmacokinetics
and DNA breakage in a multi-drug resistant B16 melanoma cell
line. Br. J. Cancer, 57, 142.
SUPINO, R., PROSPERI, E., FORMELLI, F., MARIANI, M. &
PARMIANI, G. (1986). Characterisation of a doxorubicin-resistant
murine melanoma line: studies on cross-resistance and its circum-
vention. Br. J. Cancer, 54, 33.
TWENTYMAN, P.R., FOX, N.E. & BLEEHEN, N.M. (1986a). Drug
resistance in human lung cancer cell lines: cross-resistance studies
and effects of the calcium transport blocker, verapamil. Int. J.
Radiat. Oncol. Biol. Phys., 12, 1355.
TWENTYMAN, P.R., FOX, N.E., WRIGHT, K.A. & BLEEHEN, N.M.
(1986b). Derivation and preliminary characterisation of adria-
mycin resistant lines of human lung cancer cells. Br. J. Cancer,
53, 529.
WARR, J.R., ANDERSON, M. & FERGUSSON, J. (1988). Properties of
verapamil-hypersensitive multidrug-resistant Chinese hamster
ovary cells. Cancer Res., 48, 4477.
WATSON, J.V. (1981). Dual laser beam focussing for flow cytometry
through a single crossed cylindrical lens pair. Cytometry, 1, 14.
WATSON, J.V. (1985). A method for improving light collection by
600% from square cross section flow cytometry chambers. Br. J.
Cancer, 51, 433.
WATSON, J.V., CHAMBERS, S.H. & SMITH, P.J. (1987). A pragmatic
approach to the analysis of DNA histograms with a definable
GI peak. Cytometry, 8, 1.
WATSON, J.V., SIKORA, K.E. & EVAN, G.I. (1985). A simultaneous
flow cytometric assay for c-myc oncoprotein and cellular DNA
in nuclei from paraffin embedded material. J. Immunol. Methods,
83, 179.